All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

An expert panel hosted by

The Lymphoma Hub logo and the Multiple Myeloma Hub logo

Sequencing immune-based therapies in B-cell malignancies

with Ulric Jäger, Sagar Lonial, and Krina Patel

Saturday, June 15 | 18:00-19:30 CEST

Register now

This independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.


The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.

KarMMA-2 Cohort 2B: Ide-cel in early relapse clinical high-risk MM

Jul 5, 2024
Learning objective: After reading this article, learners will be able to cite a new clinical development in multiple myeloma.

Analysis of Cohort 2B of the KarMMa-2 trial (NCT03601078) evaluating the efficacy and safety of idecabtagene vicleucel (ide-cel) in patients with high-risk, early-relapse multiple myeloma (MM) who did not receive front-line autologous stem cell transplantation (ASCT) was presented at EHA 2024 by Xavier Leleu. Of the 35 patients enrolled, 89% received ide-cel. The median age was 60 years, many had high-risk cytogenetics; 68% were double-class refractory, and 16% were triple-class refractory.

Key learnings:

In patients with newly diagnosed MM that progressed <18 months after treatment initiation, a single ide-cel infusion demonstrated a favorable benefit–risk profile with frequent, deep, durable responses and a manageable safety profile.

The overall response rate (ORR) was 94%, with a complete response rate (CR) of 71%; high minimal residual disease (MRD) negativity rates were observed at 12 and 24 months.

The median duration of response (DOR), progression-free survival (PFS), and overall survival (OS) were not reached; PFS rates were 70% at 12 months and 63% at 24 months; OS rates were 90% at 12 months and 79% at 24 months.

Grade 3/4 adverse events were experienced by 94% of patients, primarily neutropenia and thrombocytopenia; infections were identified in 19% of patients; cytokine release syndrome was observed in 84% of patients, with no Grade ≥3 cases.

These findings suggest that ide-cel offers a promising treatment for high-risk, early-relapse MM, potentially altering treatment paradigms for patients who are not candidates for ASCT.

  1. Leleu X, Chung A, Raje N, et al. Idecabtagene vicleucel (ide-cel) in patients (pts) with clinical high-risk early relapse multiple myeloma (MM) without front-line (1L) autologous stem cell transplantation (ASCT): KarMMa-2 cohort 2B. Abstract #S208 Presented at: European Hematology Association 2024 Hybrid Congress; Jun 13–16, 2024; Madrid, ES.


Subscribe to get the best content related to multiple myeloma delivered to your inbox